Abstract
Objective: We sought to evaluate performance of a noninvasive prenatal test for fetal trisomy 21 (T21) and trisomy 18 (T18). Study Design: A multicenter cohort study was performed whereby cell-free DNA from maternal plasma was analyzed. Chromosome-selective sequencing on chromosomes 21 and 18 was performed with reporting of an aneuploidy risk (High Risk or Low Risk) for each subject. Results: Of the 81 T21 cases, all were classified as High Risk for T21 and there was 1 false-positive result among the 2888 normal cases, for a sensitivity of 100% (95% confidence interval [CI], 95.5-100%) and a false-positive rate of 0.03% (95% CI, 0.002-0.20%). Of the 38 T18 cases, 37 were classified as High Risk and there were 2 false-positive results among the 2888 normal cases, for a sensitivity of 97.4% (95% CI, 86.5-99.9%) and a false-positive rate of 0.07% (95% CI, 0.02-0.25%). Conclusion: Chromosome-selective sequencing of cell-free DNA and application of an individualized risk algorithm is effective in the detection of fetal T21 and T18.
Original language | English (US) |
---|---|
Pages (from-to) | 137.e1-137.e8 |
Journal | American journal of obstetrics and gynecology |
Volume | 207 |
Issue number | 2 |
DOIs | |
State | Published - Aug 2012 |
Keywords
- Down syndrome
- aneuploidy detection
- cell-free fetal DNA
- noninvasive prenatal diagnosis
- trisomy
ASJC Scopus subject areas
- Obstetrics and Gynecology